Device: Desktop
Opening
a new frontier
in pharmacology
Opening
a new frontier
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
”
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
“
Pier Vincenzo Piazza, CEO
Latest News
Latest News
Aelis Farma announces the positive results of its clinical Phase 1/2 Study with AEF0217 in young adults with Down syndrome
November 2024
+
Results of the clinical Phase 2B Study with AEF0117 in Cannabis Use Disorder
September 2024
+